
By Benzinga : By Scott Rubin Traders who are comfortable with a high level of risk/reward frequently will gravitate to the small-cap space where big gains (and losses) in a short amount of time are commonplace. One of the strategies that momentum-oriented small-cap traders utilize is relative ...
Arena Pharmaceuticals ( ARNA ) +4.7% to $6.24 after it yesterday completed its secondary public offering and underwriters fully exercised their option to purchase additional stock. Arena sold almost 12.65M shares at $5.50 each, raising nearly $70M. Post your comment!
By Matthew Smith : Both Asia and Europe are up strongly this morning, and this could be good for our markets although currently U.S. futures are lower. It appears that maybe we are backing off due to yesterday's big day, but if we do not have any bad news out of Europe we could once again see ...
By Mina Shaker : The following is a review of three biotech stocks with potential for growth. Amarin ( AMRN ), Osiris (OSIR and Abbott ( ABT ) are three companies with either recent breakthroughs, a catalyst, or a possible place to ride out a coming storm. Amarin ( AMRN ) On Tuesday May 8th Amarin
By Matthew Smith : Markets sold off yesterday once again on news coming out of Europe. There are serious issues on the continent, and one has to ask who is in charge in Greece. We know its currently a judge, but the politicians certainly were not before, or after the elections and it is obvious ...
By Scott Matusow : In the final part of my three part series on "Hitting The Jackpot With Small Cap Bio Pharma Investment," I shift the focus to the what looks like the future of cancer treatment therapy. What if cancer could be arrested, forced into remission, and even cured by simply manipulating
Premarket gainers: OSUR +30% . COGO +15% . SINA +12% . ABMD +9% . VELT +8% . FTR +6% . Losers: CLNT -29% . JCP -15% . TAXI -9% . NBG -8% . ANF -7% . ARNA -6% . WHX -5% . KERX -5% . Post your comment!
By Helix Investment Management : Of all the sectors in the stock market, no sector moves more due to corporate developments than the biotechnology sector. A single drug trial or FDA decision can send stocks soaring, or plunging. Due to this trend, many investors choose to trade biotechnology stocks
By Mina Shaker : In case you have been sleeping under a rock, Arena Pharmaceutical's ( ARNA ) weight loss drug, Lorcaserin, was approved by an advisory board on Thursday afternoon. Friday, the stock sky rocketed up
By The Swiss Trader : When investors think of a public offering they picture a private company becoming a public company or an already public company requesting more money from investors. Initial public offerings are often very attractive to private entities because of the large premiums that ...